Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanChiara Cremolini, Daniele Santini, Filippo Pietrantonio et al.|JAMA Oncology|2018Cited by 418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Daniele Rossini et al.|The Lancet Oncology|2022Cited by 268
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J. G. Bond, Johannes J.M. Kwakman, Maarten van Smeden et al.|JCO Clinical Cancer Informatics|2024Cited by 6